Pelthos Therapeutics Reports 114% Year-over-Year Revenue Growth for Zelsuvmi in Q3 2026
Pelthos Therapeutics (PTHS) reported strong third-quarter 2026 financial results, highlighted by a 114% year-over-year increase in net revenue for its product Zelsuvmi, which reached $15.2 million. The company's management expressed confidence in its commercial trajectory and pipeline development. Looking ahead, Pelthos expects to begin promoting Xepi by the end of Q1 2027. Additionally, the company is advancing Castle Creek’s D-Fi candidate into Phase III clinical trials, signaling significant progress in its long-term drug development strategy.
Tickers: $PTHS